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Abstract: Miltefosine (hexadecylphosphocholine or HePC) is an alkylphosphocholine approved for 
the treatment of visceral and cutaneous Leishmaniasis. HePC exerts its effect by interacting with 
lipid membranes and affecting membrane-dependent processes. The molecular geometry of HePC 
suggests that the pharmacological function of HePC is to alter membrane curvature. As a model 
system, we studied the enzyme production in model membranes of diacylglycerol (DAG) or 
ceramide (CER), lipids involved in cell signaling which alter the structure of membranes. Here, we 
studied the effect of HePC on changes in phospholipase activity and on the effect that the lipid 
products have on the curvature and fusogenicity of membranes where they accumulate. Our results 
indicate that HePC inhibits the long-time restructuring of membranes, characteristic of the DAG 
and CER enzyme formation processes. In addition, the drug also reduces the fusogenicity of 
phospholipase-derived products. We postulate that the effect of HePC is due to a non-specific 
geometric compensation of HePC to the inverted cone-shape of DAG and CER products, acting as a 













mechanism of action by which HePC regulates the lipid metabolism and signal transduction 
pathways in which these enzymes are involved. 
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Miltefosine or hexadecylphosphocholine (HePC) is an alkyllysophospholipid analog. Along with 
other alkylphospholipid analog members, HePC was originally developed as an antitumor agent in 
the late 1980s. Even after HePC was approved for the treatment of cutaneous metastases in breast 
cancer patients, it was found clinically ineffective [1]. However, further studies demonstrated that 
HePC is active against most Leishmania species, including those that cause cutaneous disease. 
HePC, sold under the trade name Impavido® among others, is used against the cutaneous, mucosal 
and visceral forms of Leishmaniasis in different countries [1–5]. This treatment shows several side 
effects including vomiting, abdominal pain, fever, headaches, and decreased kidney function. 
Currently, HePC–based treatments are studied in 42 clinical trials reported in the U.S. National 
Library of Medicine (NLM-NIH) (ClinicalTrials.gov). 38 of them are for less aggressive treatment 













HePC mechanism of action against both Leishmania parasites and human cancer cells links its 
activity mainly to (i) apoptosis and (ii) disturbance of lipid-dependent cell signaling pathways[5]. In 
all cases, HePC action involves insertion into the plasma membrane as a prerequisite for drug 
uptake before the active molecule reaches its intracellular targeting. In mammalian cell cultures, 
HePC is most effective in metabolically active, proliferating cells, such as cancer cells, but not in 
quiescent normal cells [2]. HePC is active against most species of Leishmania, but not all [5]. At 
plasma membrane level, L. donovani, the causative species on the Indian subcontinent and in 
eastern Africa, show a prevalence of phosphatidylethanolamine (PE) over phosphatidylcholine (PC) 
and sphingomyelin (SM) [6]. This contrast with the occurrence in the mammalian cells plasma 
membrane, where PC prevails over SM and PE [7]. Notably, a transient treatment of Leishmania 
parasites with HePC enhances the PE and reduces PC content in the plasma membrane.  
HePC affects the biosynthesis of PC by inhibiting the rate-limiting enzyme CTP:phosphocholine 
cytidylyltransferase (CT) and altering intracellular cholesterol traffic and metabolism in human 
tumor cell lines [2,4,6,8]. HePC was also responsible for an apoptosis-like death in L. donovani, 
both in the promastigotes and amastigotes forms [9]. This drug interferes with phospholipid 
metabolism that is differentially expressed in HePC-susceptible and HePC-resistant L. donovani 
[10]. Different than mammalian cells, cholesterol is not biosynthesized in Leishmania parasites, 
which have to take it up from the external medium. Ergosterol, is also present in Leishmania 
membranes, due to biosynthesis. Total sterols account for as much as 43.3 % w/w of neutral lipids 
[11]. It has been reported that HePC has strong affinity for sterols [9,12,13] and HePC transiently 
treated parasites show an increase in its cholesterol content [6]. It is worth noting that both lipids 
increased after HePC transient treatment (PE and cholesterol) have in common its capacity for 
promoting non-lamellar lipid phases [14,15]. 
Early reports demonstrated that the activity of several enzymes of central relevance in lipid 
homeostasis and cell signaling are highly regulated by the presence of non-lamellar forming lipids. 













lipid membranes triggers the binding of several cytosolic proteins, whose membrane forms are 
metabolically active. The mechanism governing this effect correlates with an increase in the 
membrane’s stored curvature and responds to an increased surface hydrophobicity and dehydration 
[16–18]. This is the case of CT and DAG kinase [16,19,20], protein kinase C [17,21], G protein 
[22–24], and other important enzymes that regulate lipid metabolism, including several 
phospholipases [19,25,26]. In this context, it is conceivable that specific therapies could be 
designed on the basis of regulating membrane lipid structure [15]. Destabilization of nonlamellar 
membrane structures by the cytotoxic drug daunomycin has been demonstrated to promote G-
protein and PKC dissociation from the plasma membrane and disruption of cellular signaling 
pathways [27].  
It was proposed that HePC acts on CT activity by disrupting membrane curvature elastic stress and 
inhibiting membrane-associated protein activity.
  
Dymond et al. [28] evaluated the structure-activity 
relationship of alkyllysophospholipids from the literature and provided a theoretical framework for 
the hypothesis, which predicts that the most potent alkyllysophospholipid analogs will be in the 
type I lipid group. Type I lipids form aggregates whose polar–apolar interface curves away from the 
aqueous domains, which is commonly reported as ―positive‖ curvature structures, like micelles. 
HePC shows a cone-like shape and was determined to belong to type I, favoring micelles and small 
lamellar structures [12,28]. On the other hand, inverted-cone lipids (e.g. PE) forms non-lamellar 
structures with ―negative‖ curvature, such as hexagonal o cubic phases [14]. The combination of 
both groups of non-lamellar prone lipids (conic and inverted-conic shaped) would compensate their 
geometric constrains stabilizing planar lamellar phases. Direct evidence of the HePC capacity of 
perturbing highly ‖negative‖ curved lipid structures has been provided by Malheiros [29]. In this 
thesis, the addition of only 5 % w/w of HePC to cubosomes disrupts its cubic crystalline structure. 
Previous reports from our laboratory and others [12,30–32] demonstrate that the incorporation of 
HePC into the lipid interface results in changes of the physical properties of the host membrane. In 













induced by the enzyme production of DAG and ceramide (CER), both cataloged as lamellar 
disrupting lipids. These important lipid second messengers are produced by the action of 
phospholipase C (PLC) and sphingomyelinase (SMase), respectively, and have an inverted-cone 
geometry. Their membrane accumulation induces the restructuring of the lipid bilayers into 
aggregates containing non-lamellar structures with high surface curvature [26,33–36], affecting 
various cellular processes including those that involves membrane fusion [16,37]. Furthermore, 
direct evidence has been reported that enzymatically-induced changes in lipid composition regulate 
the fusion between the plasma membrane and liposomes [38].   In turn, those changes in curvature 
stress have the potential to affect the action of other important actors in lipid metabolism and 
signaling, as described above [16,19–22,24,39–41].  
Enzymes related to lipid metabolism, such as phospholipases, are very susceptible to changes in the 
physical properties of the membrane and, in turn, indirectly transmit information to other metabolic 
pathways through structural and electrostatic changes or phase state alterations of the 
biomembranes in which they act [33,41–44]. Based on these reports, here we study the effect of 
HePC on phospholipase enzyme activity and on the membrane physical property changes that the 
phospholipase products induce. Our hypothesis is that the membrane insertion of the amphiphilic 
cone-shaped alkylphospholipid HePC either directly modulates membrane curvature or 
compensates the stress generated by the inverted-cone shaped lipids produced by PLC or SMase. 
We thus address not only the biochemical but also the biophysical changes that HePC exerts when 
present in lipid membranes. Our results aid the understanding of the mechanism of action by which 
HePC regulates the lipid metabolism and signal transduction pathways. 
 
2. Materials and methods 
 













Miltefosine or Hexadecylphosphocholine (HePC), 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC), 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) and Sphingomyelin (Brain, Bovine) (SM) were purchased from 
Avanti Polar Lipids, Inc. (Alabama, U.S.A.). Fluorescent probes 1,2-dioleoyl-sn-glycerol-3-
phosphoethanolamine-N-lysamine rhodamine B sulfonyl) (ammonium salt) (Rho-PE) and 
phosphatidylethanolamine-N- (7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-PE) were from Avanti 
Polar Lipids, Inc. (Alabama, U.S.A.). For enzyme activity studies, the enzymes sphingomyelinase 
(SMase) from Bacillus cereus (EC 3.1.4.12) and phospholipase C (PLC) from porcine pancreas (EC 
3.1.1.4) were used. Both were purchased from Sigma-Aldrich (St. Louis, MO). All other reagents, 
chloroform, methanol, acetic acid, sodium chloride, Tris-Base and HPTLC (high-performance thin-
layer chromatography) silica gel 60 aluminum plates (Kieselgel 60), were purchased from Merck 
(Darmstadt, Germany). Hexane and petroleum ether were from Sintorgan (Argentina). All reagents 
were analytical grade (99% Pure) and used without further purification. Deionized water, with a 
resistivity of ~ 18 MΩ cm, was obtained from a Milli-Q Gradient System (Millipore, Bedford, MA). 
 
2.2 Methods 
2.2.1 Vesicles preparation  
Multilamellar vesicles (MLVs) containing SM:DOPE (70:30 molar ratio) or DOPC:DOPE (80:20 
molar ratio) were used in the absence and presence of 20 mol% of HePC. The MLVs were prepared 
by generating a uniform lipid film on the wall of a glass test tube. For this, 160 nmol of lipid or 
lipid/HePC mixtures were placed into glass tubes from a chloroform lipid solution and drayed by 
solvent evaporation under an N2 (g) stream. Traces of solvent were removed during 2 h treatment in 
a high vacuum chamber. The lipids were hydrated with 400 L of a buffer solution containing 10 
mM HEPES, 200 mM NaCl, 10 mM CaCl2, at pH 7 for PLC studies and with the addition of 2 mM 
MgCl2 for SMase. The samples were vigorously mixed for two min and subjected to five freeze-













was maintained for 2 min. Large unilamellar vesicles (LUVs) were prepared by extrusion (21 times) 
of MLVs through polycarbonate filters of 100 nm pore size at 45°C. The liposomes samples were 
kept at room temperature (22±2C) and used within 8 h. For fluorescent measurements, appropriate 
aliquots of the fluorescent probe Rho-PE were added to the chloroform lipid suspension, reaching 1 
mol%. 
GUVs were prepared by electroformation. Briefly, 7 μL of a lipid (POPC or bbSM) or lipid/HePC 
solution (0.5 mg/mL in chloroform: methanol 2:1 v/v), doped with 1 mol% of the fluorescent probe 
NBD-PE, were spread onto two stainless steel plates as described in the Ref. [45]. The plates were 
subjected to vacuum (1 h) to remove any remaining traces of organic solvent. The lipids were 
hydrated with a 300 mOsm sucrose solution previously filtered and heated to 60°C. The electrodes 
were connected to a homemade function generator applying otential for 1 h at 37°C for POPC or 2 
h at 60°C for bbSM vesicles, respectively. Initially, a sine wave potential of 10 Hz was applied, 
with amplitude from 0 to 2.6 V peak-to-peak potential increasing linearly in 60 s (Bartlett 
modulation), which was afterward maintained at 2.6 V peak-to-peak potential [45]. 
  
2.2.2 Enzyme Activity 
LUVs containing DOPC:DOPE (80:20 molar ratio) or SM:DOPE (70:30 molar ratio) in the absence 
and presence of 20 mol% of HePC to reach a 400 μM total lipid concentration, were incubated with 
PLC (7.5 x 10
-3 
U/ml) or Bacillus cereus SMase (1.4 U/mL) at 37°C. For temperature and stirring 
control, a Quantum Northwest (Liberty Lake, WA) TC 125 temperature controller system was used. 
Aliquots of this suspension were taken at regular intervals and chloroform:methanol (2:1) was 
added. The lower phase of the extraction system was evaporated, and the samples subjected to TLC. 
Chloroform:methanol:water (100:42:6, v/v/v) was run up to approximately one-third of the plates to 
separate PC from SM, and, after drying the plates, chloroform:methanol:acetic acid (96:4.1, v/v/v) 
was run up to the top of the plates to isolate the CER. For PLC the same procedure was used, but 













treatment with hexane:ethyl ether:acetic acid (80:20:2 v/v/v) was necessary to separate DAG. For 
lipid identification and quantification, the plates were submerged into an aqueous solution of 3% 
p/v cupric acetate, 8% v/v phosphoric acid and heated up to 90°C. Lipid semi-quantification was 
performed using the ImageJ 1.43u program (NIH). 
 
2.2.3 Effects of phospholipases on vesicle size 
Spectrophotometry and vesicle size distribution data were obtained using LUV preparations 
containing SM:DOPE or DOPC:DOPE in the absence or presence of 20 mol% of HePC, as 
described above. Samples were taken immediately before (t=0) and at specified incubation times 
after phospholipase addition. The absorbance of each sample was measured using a UV-visible 
spectrophotometer (Shimadzu UV-2401PC). Absorbance curves vs. time were measure at ʎ = 500 
nm with a slit width of 1 nm at 37°C. 
Changes in vesicle size distribution profiles resulting from PLC or SMase action were followed by 
dynamic light scattering (DLS) analysis, using a Submicron Particle Sizer (Nicomp 380, Santa 
Barbara, CA). Before enzyme treatment, LUV preparations showed a bell-shape size distribution 
centered at 100 nm. Particle size distribution profiles were traced at the different incubation times 
after PLC or SMase addition. The percentage of the volume of lipid particles larger than 250 nm 
was calculated from size distribution tracings by relating the peak areas corresponding to lipid 
particle populations greater than 250 nm to the total area. 
 
2.2.4 Confocal microscopy visualization of giant unilamellar vesicles (GUVs) 
A small aliquot of the GUV suspension (50 μL) was transferred to an 8-well observation chamber 
(Lab-Tek, Thermo Fisher Scientific, Inc.NYSE:TMO) and diluted with 300 mOsm 10mM HEPES, 
200mM NaCl, 10mM CaCl2, 2mM MgCl2 or 10mM HEPES, 200mM NaCl, 10 mM CaCl2 at pH 7 
buffer for SMase or PLC experiments, respectively. The sucrose and buffer solutions were checked 













Giessen, Germany). Before GUV addition to the well, the glass of the observation chamber was 
treated with a 10 mg/mL BSA solution, which prevented GUV rupture onto the slide. The excess of 
BSA was eliminated by several washes with buffer. The GUVs were observed with a fluorescence 
confocal microscope (Olympus FV 1000, Tokyo, Japan) with a 60x oil objective.  
For experiments to study the fusion of LUVs to GUVs, the GUVs in sucrose/buffers were mixed 
with the LUV suspension 2:1 (v/v) and this was left for 10 min before imaging by confocal 
fluorescence microscopy. GUVs doped with NBD-PE and LUVs doped with Rho-PE were 
visualized and fluorescence energy transfer was detected by selecting three different imaging 
channels; (i) the direct donor (NBD-PE) excitation at 488 nm and emission at 500-545 nm, (ii) 
donor excitation at 488 nm and acceptor (DPPE-Rh) emission at 600-700 nm, and (iii) direct 
acceptor excitation at 543 nm and emission at 600-700 nm. The laser power was kept at a minimum 
to allow a sufficient signal while avoiding bleaching. Confocal Images of GUVs were processed 
and quantified with the FIJI ImageJ software (NIH, USA). 
 
2.2.5. Statistical treatment 
Results are expressed as the mean±standard error of the mean (SEM) for three different 
experiments. Statistical comparisons were calculated by Student’s t-test using the GraphPad 
QuickCalcs Web site: http://www.graphpad.com/quickcalcs (GraphPad Software, San Diego, CA). 





3.1. HePC does not directly affect the enzyme activity of phospholipases (PLC and SMase). 
We first analyzed the effect of HePC on the enzyme activity of PLC and SMase at short times 













evaluate PLC and SMase activity, respectively. Both enzyme actions were reported in the 1990s as 
resulting in membrane aggregation and restructuring due to the accumulation of products in the 
membrane as DAG (PLC) or Cer (SMase). Those effects were enhanced by the presence of the non-
lamellar forming lipid PE [46,47]. 
The enzyme products were detected by TLC. When the LUVs composed of DOPC:DOPE were 
treated with PLC, the presence of DAG appeared in the first 6 min and its progressive increase was 
achieved, reaching 20 % of total DOPC hydrolysis both in the absence and presence of HePC 









 (HePC presence).  
 
Figure 1: Reaction course of the enzymatic production of diacylglycerol (DAG) and ceramide 
(CER), determined by thin-layer chromatography (TLC). A) PLC-driven conversion of 
glycerophospholipids to DAG in liposomes containing DOPC:DOPE (80:20 molar ratio) with or 
without the addition of 20 mol% of HePC. B) SMase-driven conversion of sphingomyelin (SM) 
to CER in liposomes containing SM:DOPE (70:30 ratio) with or without the addition of 20 mol% 
of HePC. A final lipid concentration of 0.4 mM was used. PLC (3 x 10
-4
 U / ml) or SMase (2.8 x 
10
-2 
U / ml) were added at t = 0. Incubation proceeded at 37°C for the indicated intervals, until 
stopped by the addition of the solvents required for lipid extraction. Experimental data 
correspond to the formation of DAG or CER in the absence (black symbols) and presence of 
HePC (open symbols, respectively). Error bars correspond to SD of a triplicate experiment. 
A) PLC
Time (min)
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A similar situation was observed for SMase activity on SM:DOPE LUVs. The formation of CER 
(Figure 1B) reached 20 - 30% of product formation in the first 10 minutes of the reaction. The 




) in the absence and presence of 
HePC, respectively. This indicates a statistically significant inhibition (29%; P<0.05) of the reaction 
rate by HePC.  
 
3.2. HePC inhibits PLC and SMase induced liposome fusion  
We explored the capacity of HePC to alter the highly curved membrane structures induced by the 
DAG and CER lipids. Such inverted-cone-shaped lipids are produced by the action of PLC or 
SMase on the outer hemilayer of the liposomes. Therefore, the lipid products accumulate 
asymmetrically in the membrane until the flip-flop process dissipates this translayer concentration 
gradient. Flip-flop rates for CER and DAG are in the order of ms or longer, and are somewhat 
greater for DAG than for CER [48]. Therefore, this process is on a similar time scale to that of the 
phospholipase constant rates [49,50]. This induces transient lateral curvature stresses at the 
membrane, which relax by restructuring the membrane through processes like fusion or aggregation 
where a non-lamellar intermediate occurs [34,35,51,52]. 
In this section, liposome fusion/aggregation processes after enzyme treatment were indirectly 
assessed by turbidimetry. This effect responds to an increase in lipid particle size (from  100 nm 
diameter to micrometric-size particles) that increases dispersion of light at 500 nm. Therefore, we 
analyzed the lipid particle size change by dynamic light scattering (DLS). 
When PLC is added to LUVs composed of DOPC:DOPE, an increase in turbidity is observed 















Figure 2: PLC or SMase action on vesicle aggregation. Vesicle restructuring was evidenced by the 
turbidimetry method obtaining absorbance curves vs time. (A, D) Liposome aggregation curves 
(100 nm diameter) composed of DOPC:DOPE or SM:DOPE were exposed to PLC (7.5 x 10
-3
 U / 
ml) (A) or SMase (1.4 U / ml) (D) at 37° C in absence (black line) and presence (blue or red line) 
Time (min)










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of 20 mol% of HePC. The curves in A and D are representative of triplicate experiments. (B, E) 
Comparison of absorbance values obtained at the indicated times after enzyme addition in the 
absence (gray bars) and presence (blue or red bars) of HePC. (C, F) Quantification of DAG or 
CER enzyme formation in the absence (gray bars) and presence of 20 mol% of HePC (blue and 
red bars, respectively). In all cases, the total lipid concentration was 0.4 mM. The experiments 
were performed in triplicate, average values ±SEM (n = 3). Asterisks indicate statistical 
differences of data obtained in similar conditions in the absence and presence of HePC with P 
<0.05 (*) or P <0.0001 (**). 
 
This effect was first observed in the early 1990s by Felix Goñi et al. and was interpreted in terms of 
liposome aggregation and fusion [46,47]. The addition of 20 mol% of HePC to our system clearly 
showed a drastic decrease in vesicle aggregation, evidenced by a slower absorbance increase 
observed after enzyme addition (Figure 2A). This effect was quantified at 6 and 60 min, showing a 
decrease in absorbance in the presence of HePC of 95 and 82%, respectively, in comparison to 
conditions in the absence of the drug (Figure 2B).  
Additionally, there were no significant differences in the amount of DAG formation at 6 min in the 
absence and presence of HePC (Figure 2C and 1A). This demonstrates that, even when a similar 
amount of DAG is produced, HePC is impairing liposome fusion/aggregation. On the other hand, 
after 60 min of enzyme treatment, DAG production was reduced to a fourth (from 68±9 % to 18±5 
%, see Figure 2C), while vesicle aggregation, evidenced by an absorbance reduction, decreases to 
less than a sixth by the presence of HePC (from 1.02±0.08 to 0.14±0.01, see Figure 2B). Therefore, 
even when a significant amount of DAG is produced, its effect on membrane restructuring is still 
hampered by HePC. 
Early reports demonstrated that full PLC activity requires the presence of membrane surface 
irregularities or defects induced by the product DAG causing vesicle aggregation [53]. Our results 













inhibition of vesicle aggregation. Therefore, we infer that HePC acts indirectly on PLC activity by 
somehow relaxing the curvature stress induced by DAG and thus inhibits full PLC activity. 
 
Figure 3: Changes in vesicle size distribution profiles as a consequence of PLC or SMase action 
followed by dynamic light scattering (DLS) analysis. Representative graphs of differences in the 


































































































































































































































































































SM:DOPE (D, E) before (black symbols) and after 60 min of PLC or 40 min of SMase treatment 
(colored symbols). Comparison of the size distribution of LUVs in the absence (A, D) and the 
presence of 20 mol% HePC (B, E). The vertical dashed lines in A-B and D-E divide the particles 
smaller than the larger than 250 nm. The data is the average values ± SEM of triplicate 
experiments. (C, F) Analysis of the number of lipid particles larger than 250 nm as a percentage of 
the total population, calculated as the integral of the particle volume distribution curves vs 
diameter. Liposome and enzyme conditions are similar to those described in the legend of Figure 
2. Asterisks in panels C and F indicate statistical differences of data with P <0.05 (*) or P <0.0001 
(**). 
 
The formation of large lipid particles by the action of PLC was confirmed by DLS (Figure 3A-C). 
Both vesicles, containing HePC or not, showed a particles population, with a size distribution 
centered at 100 nm before enzyme treatment (Figure 3A, black symbols). On the other hand, LUV 
suspensions containing HePC showed a small population close to 10 nm (corresponding to less than 
8% of the total particle volume), which are HePC-enriched micelles (Figure 3B, black symbols) 
[12].  
As can be observed from Figure 3, the liposomes of any composition were smaller than 250 nm 
before enzymatic treatment (black symbols in Figure 3A, B, D and E). Therefore, the occurrence of 
particles larger than 250 nm after the addition of enzymes has been taken as a consequence of 
liposome aggregation upon the generation of CER or DAG. 
The enzyme production of DAG by PLC induced the appearance of a population of large particles 
(micrometric size), shifting the particle size distribution to a diameter range above 250 nm (Figure 
3A, blue symbols). The presence of HePC reduces this effect (Figure 3B, blue symbols). A more 
detailed analysis shows that in the presence of HePC only~ 45% of the particle volume was 
organized in structures larger than 250 nm after treatment with PLC (Figure 3C). This matches the 
turbidity measurements, indicating that HePC reduces the vesicle aggregation process induced by 













Similar behavior was observed with the addition of SMase to liposomes of SM:DOPE in the 
absence and presence of HePC. There was an increase in turbidity over time (Figure 2D) with an 
abrupt increase in turbidity in the first 5 min of reaction in the absence of HePC, as reported before 
[46], and a further slow relaxation of the process (Figure 2D). The presence of HePC slows down 
the turbidity time-curve, reaching only a third of that observed in the absence of the drug at 10 min 
of reaction. Notably, over long periods the inverse relation is observed (Figure 2E), evidencing the 
occurrence of far-from-equilibrium processes related to vesicle aggregation that anneals over time.  
The quantitative analysis of the extent of hydrolysis of SM in the absence and presence of HePC at 
10 and 40 min is shown in Figure 2F. Both at short and long times, the presence of HePC induces 
up to 25% inhibition of the amount of CER formed. This shows that HePC affects SMase-
dependent liposome aggregation to a greater extent than its enzyme activity. Therefore, HePC 
hinders the effect that CER exerts on the membrane physical properties, relaxing its curvature stress 
and fusogenicity, as will be discussed in the next section.  
In the absence of SMase, the LUVs containing SM16:DOPE showed a population of vesicles with a 
diameter peak at 100 nm (Figure 3D, black symbols). Vesicles containing 20 mol% HePC also 
showed the presence of a smaller population of particles centered at 50 nm (Figure 3E, black 
symbols), in agreement with previous observations [12]. Enzyme hydrolysis of SM induced 
polydispersion in the particle distribution histogram, with a population larger than 250 nm both in 
the absence and in the presence of HePC (Figure 3D, E, red symbols). However, at short reaction 
times, the percentage of particle volume with a diameter larger than 250 nm is significantly smaller 
in the presence than in the absence of HePC (Figure 3F), confirming the turbidimetry assays. In 
summary, HePC slows down the aggregation of vesicles subjected to the rapid action of SMase at 
short times, probably because it relaxes the topographic frustration generated by CER by having a 
complementary symmetry. However, at long times, the action of SMase prevails and aggregated 
structures appear, which allow the evolution of catalysis to similar values to those obtained in the 













3.3. HePC inhibits LUV-GUV fusion  
From the results shown in the previous section and bibliography data [35,36,46,53], we can 
conclude that vesicles containing enzymatically generated CER or DAG show fusogenic properties. 
Furthermore, these properties are inhibited by the presence of HePC. Taking into account that 
membrane fusion is at the heart of many essential cellular processes, such as intracellular trafficking 
and signaling via endo/lysosome fusion [51], and that those are proposed as target processes in 
HePC action [8], we further explored the effect of HePC on fusogenic liposomes, using giant 
unilamellar vesicles (GUVs) as a fusion target. Those micron-sized vesicles can be visualized 
directly under a fluorescence confocal microscope. They are flat at the molecular level, making 
them very useful mimics of the plasma membrane [51]. 
We performed a fusion assay by adapting the procedure described by Lira et al. [54]. In this system, 
LUVs, which are the substrate of the phospholipase, are labeled with the lipophilic probe NBD-PE 
and are mixed with Rho-PE-labeled GUVs designed as non-substrate. Vesicle fusion after enzyme 
addition is detected by two means: I) through the morphological changes of GUVs observed by 
confocal microscopy upon enrichment with the non-lamellar forming lipids DOPE and CER or 
DAG, and II) lipid mixing increases fluorescence resonance energy transfer (FRET) between the 
two probes and the red emission of the acceptor probe increases at expense of the emission of the 
donor (green), upon excitation of the donor probe. 
GUVs composed of SM and labeled with the fluorescent probe NBD-PE were observed by confocal 














Figure 4: Confocal microscopy images of GUVs of SM labeled with NBD-PE (green) and 
fusogenic Rho-PE-labeled LUVs (red) composed of DOPC:DOPE (80:20) in the absence (upper 
panel) or presence (lower panel) of 20 mol% of HePC. The timestamps indicate the time after 
PLC addition. Fluorescence intensity profiles for the green and red channel in the GUV regions 
along the dashed lines are plotted under each image. Samples were excited at the NBD-PE 
excitation  and images show the overlay of NBD-PE and Rho-PE emission channels. 
 
LUVs composed of DOPC:DOPE:Rho-PE were used as the substrate of PLC. The addition of the 
enzyme to a LUV/GUV mixture triggered DAG formation in LUVs. Its fusion to the GUV 
membrane was evidenced by an increase in the red/green fluorescence ratio (increase in the FRET 
signal) at 30 min that doubled the initial value (Figure 6A). Concomitantly, changes in GUV shape 
were observed, which evidenced the occurrence of membrane areas with high curvature (see Figure 
4). This may be explained by concentration of the non-lamellar forming lipids DOPE and DAG 
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originated in the PLC-treated LUVs. The changes in shape were observed in 94% of the GUVs 
analyzed (n=47) after 60 min of PLC treatment (see Figure S1 for image gallery and video_PLC in 
support information). Control experiments carried out in the presence of 100 mM EDTA, a 
condition where PLC is inhibited, did not show shape changes in GUVs (Figure S1). 
When 20 mol% of HePC was present in the LUVs, their fusion to GUV membranes was reduced, as 
reflected by the low values of the red/green fluorescence ratio, which is statistically different than 
that observed in the absence of HePC (Figure 6A). As a consequence of the low extent of fusion 
and the presence of the cone-shaped HePC, GUVs incubated with this system showed no shape 
change (only 7% of non-circular GUVs were found, n= 85; see Figure 4 and video_PLC_HePC in 
support information). 
GUVs formed by POPC and labeled with the fluorescent probe NBD-PE were observed by confocal 
microscopy as circles when focused on the equatorial plane (Figure 5). Liposomes composed of 
SM:DOPE:Rho-PE were used as the substrate of SMase. The addition of the enzyme to a 
LUV/GUV mixture triggers CER formation in LUVs. After a few minutes, red dots were observed 
attached to GUV (green) membranes (Figure 5 and video_SMase in support information).  
This effect has been interpreted as liposome docking in a similar system [54]. In this stage, LUVs 
associated with but did not mix with the GUV lipid membrane. As the enzyme reaction progressed, 
the GUV membranes showed a significant increase in red fluorescent content (see Figure 6B) due to 
a burst in LUV fusion to GUVs, until GUVs collapsed in a non-lamellar lipid structure (Figure 5, 














Figure 5: Confocal microscopy images of GUVs of POPC labeled with NBD-PE (green) and 
fusogenic Rho-PE-labeled LUVs (red) containing SM:DOPE (80:20) in the absence (upper 
panel) or presence (lower panel) of 20 mol% of HePC. The timestamps indicate the time after 
SMase addition. Fluorescence intensity profiles for the green and red channel in the GUV regions 
along the dashed lines are plotted under each image. Samples were excited at the NBD-PE 
excitation  and images show the overlay of NBD-PE and Rho-PE emission channels.  
 
After 10 min incubation time, the acceptor emission signal reached intensity values 25-30 higher 
than the donor emission (Figure 6B). At 30 min of enzyme treatment, microscopy images showed 
the presence of amorphous lipid clusters coming from collapsed GUVs, as well as an increase of 
GUVs aggregated in groups (see Figure S2). The LUV/GUV mixed solution in the absence of 
SMase, or in the presence of SMase + 100 mM EDTA, was stable over 30 min (Figure S2).  
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Figure 6: Semiquantitative analysis of fluorescence intensity of red/ green channels ratio for images 
of GUVs composed of POPC or SM/NBD-PE, and fusogenic LUVs labeled with Rho-PE over 
time. Vesicles composed of DOPC:DOPE (A) or SM:DOPE (B) in the absence (gray bars) or 
presence (blue or red bars) of 20 mol% of HePC were incubated with GUVs and PLC (A) or SMase 
(B) and analyzed over the reaction time. As a control, GUVs labeled with NBD-PE were included. 
n >30 GUVs were analyzed for each condition. Error bars correspond to SD. * indicates statistical 
differences of data obtained in similar conditions in the absence and presence of HePC with P 
<0.0001.  
 
GUV collapse has been reported in vesicles subjected to the enzyme production of CER with very-
long-chain polyunsaturated fatty acids [35]. Notably, in the present study, this membrane 
restructuring occurred in a trans-configuration, involving the production of CER in the LUVs, lipid 
transfer to GUV membranes and finally bilayer destabilization. The addition of 20 mol% of HePC 
reduced GUV destabilization after SMase treatment of the LUV/GUV mixed system (Figure 5 and 
vodeo_SMase_HePC), showing a slight increase in the red/green fluorescence ratio (Figure 6B), 
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Our results indicate that HePC does not significantly influence the initial rate of reactions catalyzed 
by PLC or SMase. However, the extent of hydrolysis is inhibited by HePC over longer times. This 
effect was interpreted as a consequence of the inhibition of the membrane restructuring that allows 
full catalytic activity for PLC [53] and SMase [55,56]. In this work, we used SMase from a bacterial 
source, Bacillus cereus, and porcine pancreatic PLC because of its availability and extensive use in 
similar studies by other authors [46]. This might hamper the extrapolation of our results to a 
eukaryotic cellular environment due to differences in the catalytic mechanism and regulation 
properties of those enzymes with their intracellular counterparts. However, the effect of the 
accumulation of the DAG and CER products in biomembranes is expected to have similar 
consequences on the alteration of the physical properties of the membranes, regardless of their 
origin [33,37,57–59].  
Phospholipases such as PLC and SMase act on the external hemilayer of vesicles, and access of the 
enzyme to the substrates located in the inner hemilayer is impaired. In this picture, membrane 
restructuring with the occurrence of nuclei of non-lamellar phases allows not only access to all the 
substrate population [56], but also permits the lipid product to dissipate into both hemilayers, 
reducing inhibition by product. The hindering of this membrane restructuring by HePC has in turn a 
dampening effect on enzyme hydrolysis over longer times. 
This complex landscape is reflected in previous reports where HePC affects several phospholipases 
differently. HePC has been found to inhibit PLC [60,61] but not phospholipase D or SMase [62]. 
Furthermore, those authors reported differential regulation of phospholipase A2 (PLA2) by HePC, 
which cannot be explained by changes in membrane composition [63]. This suggests that 
phospholipase regulation should be understood in a non-classical way, taking into account not only 
the biochemical aspects but also the biophysical properties of the host membrane and its bi-













As commented above, the phospholipase-driven catalytic process occurs asymmetrically, since 
these enzymes act only on the outer hemilayer of the membrane. DAG and CER are lipids with a 
small polar head compared to the two bulky hydrocarbon chains of its hydrophobic region, giving it 
a general inverted cone geometry. When the kinetics of the production of those lipids is faster than 
the flip-flop dynamics, the resultant membrane is highly stressed and in a state far from its 
compositional and curvature balance [52]. GUVs subjected to the asymmetric action of SMase relax 
this frustration into the formation of highly curved vesicles associated with the mother GUV [34]. 
This whole panorama favors the aggregation of vesicles with the formation of intermediate 
structures with highly negative curvature, which relaxes the geometric tension. Therefore, DAG and 
CER, as well as PE, are considered fusogenic molecules acting by stabilizing those highly curved 
membrane regions and promoting fusion events [33,35]. 
Whist HePC mechanism of action clearly involves cell membrane alteration [2], how this alteration 
propagates to the final target enzymes involved in lipid homeostasis and cell signaling is still under 
debate. Liquid-ordered (LO) nanodomains enriched in sterols and sphingolipids, named ―lipid rafts‖ 
occur in living cell membranes and regulate important cell functions. Some authors have reported 
alkylphospholipids involvement in lipid raft stability, metabolism and apoptosis [2,9]. On the other 
hand, previous works from our laboratory evidenced that the presence of HePC destabilizes LO 
domains in cholesterol/phospholipid monolayers [12]. In agreement, Castro et al. concluded that the 
mechanism of action of alkylphospholipids is unlikely to be directly linked to alterations of lipid 
rafts biophysical properties caused by these drugs [31].  
Taking into account the discrepancy on the effect of HePC on the lateral segregation of lipids, we 
explored a different aspect of membrane alteration, which involves membrane curvature stress 
modulation, following Dymond et al. predictions [28]. The results shown in this work robustly 
demonstrate that HePC inhibits membrane restructuring events, characteristic of the enzyme 
formation process of DAG and CER. HePC is a single-tailed alkylphospholipid analog that has an 













inserted into the bilayers can induce a positive curvature, counteracting the effect caused by DAG 
or CER. Therefore, HePC relaxes the curvature-tension of the enzymatically-treated membranes 
and restricts bilayer destabilization. It impedes those signaling messengers from diffusing laterally 
with continuity towards the membranes of other vesicles. It is worth noting that our results show 
that HePC inhibits the shape remodeling of lipid membranes which are not enzyme-substrate but 
interact with enzyme-treated vesicles. Thus, the effect of HePC influences cascades of events that 
overcome the local environment of enzyme activity.   
This work focused on the action of HePC on two structurally unrelated enzymes, which degrade 
structurally different lipids (glycerol and sphingophospholipids), having in common that the 
products contain small polar groups and inverted cone structures. However, our results suggest that 
HePC may act in a non-classical way, and may influence not only those two enzymes but a greater 
variety of membrane-bound enzymes sensitive to curvature stress [16,18,19,21].  A recent report 
highlights the relationship between membrane curvature elastic stress and phospholipid homeostasis 
[18], the main target of HePC action in cells. Notably, HePC-resistant Leishmania promastigotes 
and HePC transiently treated parasites show a modification in their membrane lipid profile [6,10]. 
This lipid regulation may have the capacity to compensate for the non-specific alteration of the 
intrinsic curvature of the membrane caused by HePC. 
In summary, the results reported in this work contribute to understanding the mechanism of action 
by which HePC regulates lipid metabolism and the transduction pathways of signals and offers 
evidence of a more holistic effect of HePC. 
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 Miltefosine (hexadecylphosphocholine or HePC) alters phospholipases action. 
 HePC inhibits diacylglycerol and ceramide-induced liposome aggregation. 
 HePC inhibit membrane fusion induced by phospholipase C and sphingomyelinase action 
 HePC would act through relaxation of membrane curvature stress 
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